This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dorfman, D. M. Articles by Shahsafaei, A. Search for Related Content PubMed PubMed Citation Articles by Dorfman, D. M. Articles by Shahsafaei, A.

(American Journal of Pathology. 2003;162:1539-1544.)
© 2003 American Society for Investigative Pathology

Loss of Expression of the WNT/ß-Catenin-Signaling Pathway Transcription Factors Lymphoid Enhancer Factor-1 (LEF-1) and T Cell Factor-1 (TCF-1) in a Subset of Peripheral T Cell Lymphomas

From the Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

T cell factor-1 (TCF-1) and lymphoid enhancer factor-1 (LEF-1), members of the TCF/LEF family of transcription factors, play a significant role in T cell development and are expressed in thymocytes and peripheral CD3+ T cells. Previously, precursor T lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LyL) was found to express TCF-1, and we find that 9 of 10 cases of T-ALL/LyL express LEF-1 as well as TCF-1, exhibiting uniform nuclear immunostaining for both transcription factors. In addition, a significant subset of cases of peripheral T cell lymphoma (PTCL), 39 of 81 cases (48%), are immunoreactive for LEF-1 and/or TCF-1, with 36 of 38 cases immunoreactive for both, indicating that these transcription factors are coordinately expressed in PTCL. The vast majority of LEF-1+ and/or TCF-1+ PTCL (34 of 39 or 87%) exhibit a composite Th1 T-cell-like immunophenotype, based on expression of Th1 T cell-associated, but not Th2 T cell-associated, chemokine receptors and activation markers. Of the Th1-like PTCL studied, 33 of 42 (79%) were immunoreactive for LEF-1 and 32 of 42 (76%) were immunoreactive for TCF-1, including most cases of angioimmunoblastic lymphoma and all cases of lymphoepithelioid lymphoma. Surprisingly, none of the 21 cases of Th2-like PTCL studied, all cases of anaplastic large cell lymphoma, were immunoreactive for LEF-1 or TCF-1 (P < 0.0001), suggesting that LEF-1 and TCF-1 transcription factor expression may be lost in Th2 T cells or Th2-like PTCL. LEF-1 and TCF-1 immunostaining can serve to identify specific subtypes of PTCL, and lends support to a bipartite model of PTCL development, based on expression of activation markers.

This article has been cited by other articles:

				L. Jin, Y. Li, C.-J. Chen, M. A. Sherman, K. Le, and J. E. Shively Direct Interaction of Tumor Suppressor CEACAM1 with Beta Catenin: Identification of Key Residues in the Long Cytoplasmic Domain Experimental Biology and Medicine, July 1, 2008; 233(7): 849 - 859. [Abstract] [Full Text] [PDF]

				J. Shin, S. Monti, D. J. Aires, M. Duvic, T. Golub, D. A. Jones, and T. S. Kupper Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome Blood, October 15, 2007; 110(8): 3015 - 3027. [Abstract] [Full Text] [PDF]

				A. Bosco, K. L. McKenna, C. J. Devitt, M. J. Firth, P. D. Sly, and P. G. Holt Identification of novel th2-associated genes in T memory responses to allergens. J. Immunol., April 15, 2006; 176(8): 4766 - 4777. [Abstract] [Full Text] [PDF]

				C.-W. Lin, T.-Y. Liu, S.-U. Chen, K.-T. Wang, L. J. Medeiros, and S.-M. Hsu CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features Blood, November 15, 2005; 106(10): 3567 - 3574. [Abstract] [Full Text] [PDF]

				Z. Lin, D. K. Crockett, S. D. Jenson, M. S. Lim, and K. S. J. Elenitoba-Johnson Quantitative Proteomic and Transcriptional Analysis of the Response to the p38 Mitogen-activated Protein Kinase Inhibitor SB203580 in Transformed Follicular Lymphoma Cells Mol. Cell. Proteomics, August 1, 2004; 3(8): 820 - 833. [Abstract] [Full Text] [PDF]